Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study
- 189 Downloads
It is generally accepted that impaired cognitive function is a core feature of schizophrenia. There is evidence for the role of brain-derived neurotrophic factor (BDNF) in cognitive function. Olanzapine was reported to yield cognitive improvement in patients with schizophrenia.
In this study, we performed a prospective, open-label, 12-week observation trial to investigate whether peripheral BDNF may represent a potential biomarker for the effect of cognitive improvement induced by olanzapine in patients with schizophrenia.
In total, 95 patients with acute schizophrenia were enrolled in the study. We also recruited 72 healthy individuals for a control group. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate symptom severity and treatment response. Cognitive function was evaluated using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Plasma BDNF levels were measured with an enzyme-linked immunosorbent assay.
Of the 95 patients consented into the study, 68 completed the 12-week follow up. Our results showed that schizophrenia patients with acute exacerbation had significantly poorer performance than that of the controls (Ps < 0.01). A significantly decreased plasma level of BDNF in patients was observed compared with the controls (F = 7.77, P = 0.006). A significant improvement in each PANSS subscore and total score was observed when the patients completed this study (Ps < 0.01). Additionally, 12-week olanzapine treatment exhibited significant improvements in RBANS immediate memory, attention, and total scores (P = 0.018, 0.001, and 0.007, respectively). Along with the clinical improvement, plasma BDNF levels after 12-week olanzapine monotherapy (4.67 ± 1.74 ng/ml) were also significantly increased compared with those at baseline (3.38 ± 2.11 ng/ml) (P < 0.01). Spearman’s correlation analysis showed that the increase in plasma levels of BDNF is significantly correlated with the change in the RBANS total scores (r = 0.28, P = 0.02) but not with the change in the PANSS total scores (r = − 0.18, P = 0.13). There is a significant correlation of BDNF increase with the change of RBANS attention subscore (r = 0.27, P = 0.028).
Our findings suggest that olanzapine improves psychiatric symptoms and cognitive dysfunction, particularly attention and immediate memory, in patients with acute schizophrenia, in parallel with increased plasma BDNF levels. Plasma BDNF levels may be a potential biomarker for cognitive recovery in acute schizophrenia.
KeywordsOlanzapine Cognitive function Brain-derived neurotrophic factor Biomarker Schizophrenia
We are deeply grateful to all participants.
This work was supported by the National Natural Science Foundation of China (81471358 and 81671326), the Shanghai Science and Technology Commission Foundation (14411969000), the Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (20152530), the Shanghai Municipal Commission of Health and Family Planning Foundation (201540029), and the Shanghai Municipal Commission of Health and Family Planning, Key Developing Disciplines (2015ZB0405).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Carrion RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA (2011) Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry 168(8):806–813. https://doi.org/10.1176/appi.ajp.2011.10081209 CrossRefPubMedPubMedCentralGoogle Scholar
- Chang WC, Hui CLM, Tang JYM, Wong GHY, Chan SKW, Lee EHM, Chen EYH (2013) Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychol Med 43(09):1883–1893. https://doi.org/10.1017/S0033291712002838 CrossRefPubMedGoogle Scholar
- Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Dev 9(5):580–586Google Scholar
- Li ZZ, Zhang C, Fan JB, Yuan CM, Huang J, Chen J, Yi ZH, Wang ZW, Hong W, Wang Y, Lu WH, Guan YT, Wu ZG, Su YS, Cao L, Hu YY, Hao Y, Liu MY, Yu SY, Cui DH, Xu L, Song YY, Fang YR (2014) Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry 205(01):29–35. https://doi.org/10.1192/bjp.bp.113.134064 CrossRefPubMedGoogle Scholar
- Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, Fang ZH, Lee BJ, Kim YH (2011) Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 71(4):335–340. https://doi.org/10.1016/j.neures.2011.08.010 CrossRefPubMedGoogle Scholar
- Qin XY, Wu HT, Cao C, Loh YP, Cheng Y (2017) A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia. Mol Psychiatry 22:1206–1212Google Scholar
- Scharfman HE, MacLusky NJ (2006) Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol 27(4):415–435. https://doi.org/10.1016/j.yfrne.2006.09.004 CrossRefPubMedPubMedCentralGoogle Scholar
- Subramaniam K, Luks TL, Garrett C, Chung C, Fisher M, Nagarajan S, Vinogradov S (2014) Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains. NeuroImage 99:281–292. https://doi.org/10.1016/j.neuroimage.2014.05.057 CrossRefPubMedPubMedCentralGoogle Scholar
- Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, Bai YM (2011) Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. NeuroMolecular Med 13(4):328–333. https://doi.org/10.1007/s12017-011-8159-5 CrossRefPubMedGoogle Scholar
- Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347. https://doi.org/10.1002/wps.20252 CrossRefPubMedPubMedCentralGoogle Scholar
- Wang CH, Li Y, Yang J, Su LY, Geng YG, Li H, Wang JK, Mu JL (2013) A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res 144(1-3):129–135. https://doi.org/10.1016/j.schres.2012.12.021 CrossRefPubMedGoogle Scholar
- Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7(8):e42676. https://doi.org/10.1371/journal.pone.0042676 CrossRefPubMedPubMedCentralGoogle Scholar
- Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Muller DJ, Kennedy JL (2012) The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuro-Psychopharmacol Biol Psychiatry 39(1):96–101. https://doi.org/10.1016/j.pnpbp.2012.05.014 CrossRefGoogle Scholar
- Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, Shen Y, Haile CN, Kosten TA, Kosten TR (2007) Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 41(12):997–1004. https://doi.org/10.1016/j.jpsychires.2006.08.007 CrossRefPubMedGoogle Scholar
- Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, Li J, Lu L, Kosten TA, Kosten TR (2008) BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 33(9):2200–2205. https://doi.org/10.1038/sj.npp.1301619 CrossRefPubMedGoogle Scholar
- Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, Zhang C (2013) Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PLoS One 8(8):e72652. https://doi.org/10.1371/journal.pone.0072652 CrossRefPubMedPubMedCentralGoogle Scholar
- Zhang C, Cai J, Zhang JT, Li ZZ, Guo ZW, Zhang X, Lu WH, Zhang Y, Yuan AH, Yu SY, Fang YR (2014a) Genetic modulation of working memory deficits by ankyrin 3 gene in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 50:110–115. https://doi.org/10.1016/j.pnpbp.2013.12.010 CrossRefGoogle Scholar
- Zhang C, Chen MJ, Wu GJ, Wang ZW, Rao SZ, Zhang Y, Yi ZH, Yang WM, Gao KM, Song LS (2016) Effectiveness of antipsychotic drugs for 24-month maintenance treatment in first-episode schizophrenia: evidence from a community-based "real-world" study. J Clin Psychiatry 77:e1460–e1466CrossRefPubMedGoogle Scholar
- Zhang C, Fang X, Yao P, Mao Y, Cai J, Zhang Y, Chen M, Fan W, Tang W, Song L (2017) Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha. Psychoneuroendocrinology 81:138–143. https://doi.org/10.1016/j.psyneuen.2017.04.014 CrossRefPubMedGoogle Scholar
- Zhao G, Zhang C, Chen J, Su Y, Zhou R, Wang F, Xia W, Huang J, Wang Z, Hu Y, Cao L, Guo X, Yuan C, Wang Y, Yi Z, Lu W, Wu Y, Wu Z, Hong W, Peng D, Fang Y (2017) Ratio of mBDNF to proBDNF for differential diagnosis of major depressive disorder and bipolar depression. Mol Neurobiol 54(7):5573–5582. https://doi.org/10.1007/s12035-016-0098-6 CrossRefPubMedGoogle Scholar